Extracellular vesicles produced in B cells deliver tumor suppressor miR-335 to breast cancer cells disrupting oncogenic programming in vitro and in vivo

The successful implementation of miRNA (miR) therapies in humans will ultimately rely on the use of vehicles with improved cellular delivery capability. Here we tested a new system that leverages extracellular vesicles (EVs) laden with a tumor suppressor miRNA (miR-335) produced in B cells by plasmi...

Descripción completa

Detalles Bibliográficos
Autores principales: Almanza, Gonzalo, Rodvold, Jeffrey J., Tsui, Brian, Jepsen, Kristen, Carter, Hannah, Zanetti, Maurizio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6279829/
https://www.ncbi.nlm.nih.gov/pubmed/30514916
http://dx.doi.org/10.1038/s41598-018-35968-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6279829/
https://www.ncbi.nlm.nih.gov/pubmed/30514916
http://dx.doi.org/10.1038/s41598-018-35968-2

Ejemplares similares